Advances in GBM therapeutics have introduced novel approaches, including targeted therapies (e.g., EGFR inhibitors), immunotherapies such as ICIs and CAR-T cell therapies, and noninvasive modalities such as the tumor-treating field (TTF) (Fig. 7). Here, EGFR is linked to glioblastoma.